Lutris Pharma Completes Enrollment in Phase 2 Trial of LUT014 for the Treatment of EGFRI-Induced Acneiform Rash in Patients with Metastatic Colorectal Cancer
Topline Results Expected in Q1 2025 Lutris Pharma, a clinical stage biopharmaceutical company focused onimprovinganti-cancertherapies byreducingcutaneous doselimiting toxicity, today announced that it has completed enrollment in the phase 2 trial of lead compound, LUT014, a topically-applied novel B-Raf inhibitor, for patients with metastatic colorectal cancer (mCRC) treated with epidermal growth factor receptor (EGFR) inhibitor therapy […]